Mark Jacobson
Chief Operating Officer bij AXSOME THERAPEUTICS, INC.
Vermogen: - $ op 31-03-2024
Profiel
Mark L.
Jacobson is currently the Chief Operating Officer at Axsome Therapeutics, Inc. He previously worked as the Director of Corporate Development at Stemline Therapeutics, Inc. from 2009 to 2014.
Mr. Jacobson received his graduate degree from The Trustees of Columbia University in The City of New York in 2010 and his undergraduate degree from Iowa State University in 2006.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Mark Jacobson
| Bedrijven | Functie | Begin |
|---|---|---|
| AXSOME THERAPEUTICS, INC. | Chief Operating Officer | 01-04-2014 |
Eerdere bekende functies van Mark Jacobson
| Bedrijven | Functie | Einde |
|---|---|---|
| STEMLINE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-03-2014 |
Opleiding van Mark Jacobson
| The Trustees of Columbia University in The City of New York | Graduate Degree |
| Iowa State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| AXSOME THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Stemline Therapeutics, Inc.
 Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
